Stratified Prognostic Comparison Between Stage IIB-IVA Cervical Adenocarcinoma and Squamous Cell Carcinoma: A SEER Database-Based Study
Huimin Guo,Songkun Gao,Weimin Kong
DOI: https://doi.org/10.2147/ijwh.s446644
2024-04-04
International Journal of Women s Health
Abstract:Huimin Guo, 1, &ast Songkun Gao, 2, &ast Weimin Kong 1 1 Gynecology Department, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, People's Republic of China; 2 Gynecologic Oncology Department, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Weimin Kong, Gynecology Department, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100006, People's Republic of China, Email Objective: In current most observational studies, the prognosis of cervical adenocarcinoma is worse than that of cervical squamous cell carcinoma. However, most of the current studies are holistic and lack more detailed staging and grouping analysis of the prognosis of the two types of cervical tumors. Patients and Methods: Inclusion from the SEER database of stage IIB-IVA cervical squamous cell carcinoma and cervical adenocarcinoma patients who did not undergo surgery from 2000 to 2019, underwent radiotherapy/chemotherapy/radiotherapy and chemotherapy/no treatment, and then propensity score matching (PSM) was performed to eliminate confounding factors between cervical squamous cell carcinoma and cervical adenocarcinoma patients with the same stage and treatment method. After matching the original data and propensity score, logarithmic rank test and chi square test were used to evaluate the survival benefits of different stages and treatment methods for patients using Kaplan Meier curve. The prognosis of two types of cervical tumors under the same treatment method was compared, and factors that may cause poor prognosis were analyzed, excluding confounding factors. Results: A total of 10,057 patients were included in this study, and survival analysis showed a significant correlation between the treatment method used and patient prognosis (P< 0.05). However, for patients who received radiotherapy or no special treatment, OS and CSS were only related to tumor stage and not to tumor type. In patients undergoing radiotherapy and chemotherapy, the OS and CSS of stage IIIA and IVA patients are not related to tumor pathological characteristics, while the OS of stage IIB patients is not related to tumor properties after PSM. Conclusion: In patients undergoing radiotherapy and chemotherapy, the OS and CSS of stage IIIA and IVA patients were not related to histological type, while the OS of stage IIB patients was not related to histological type after PSM. Keywords: cervical squamous cell carcinoma, cervical adenocarcinoma, staging, prognosis, SEER Cervical cancer was once one of the most common malignant tumors in women. With the promotion of cytological screening programs and the vaccination of human papillomavirus (HPV) vaccine, the incidence rate and mortality of cervical cancer have significantly decreased. 1 Pathological diagnosis shows that most cervical cancer is squamous cell carcinoma of the cervix caused by HPV, but the true incidence rate and relative incidence rate of cervical adenocarcinoma with unclear relationship with HPV continue to rise. 2,3 Cervical adenocarcinoma is considered a type of cervical cancer with different causes and clinical outcomes compared to cervical squamous cell carcinoma. In the 5th edition of the WHO classification of female reproductive organ tumors, 4 cervical adenocarcinoma is listed separately and Silva staging is recommended to evaluate patient prognosis. In the current NCCN guidelines for cervical adenocarcinoma and squamous cell carcinoma, radical surgery is recommended for patients with stage I–IIA, and radiotherapy and chemotherapy are preferred for patients with stage IIB and above. However, previous guidelines have not separately distinguished cervical adenocarcinoma from cervical squamous cell carcinoma and the treatment plan was made according to FIGO staging. Current studies and comparisons on cervical adenocarcinoma and squamous cell carcinoma show that there are differences in treatment and survival rates between them, 5–7 and these studies mostly use conventional methods. In small sample studies, the prognosis of cervical adenocarcinoma is significantly worse than that of cervical squamous cell carcinoma. 5,8 In large sample analysis, the incidence of AC is related to age and race. 3 These differences may lead to different patient outcomes under the same treatment method, and there are significant differences in the situation of adv -Abstract Truncated-
obstetrics & gynecology